CVT-313
CAS No. 199986-75-9
CVT-313( CVT-313 | CVT 313 | CVT313 )
Catalog No. M17417 CAS No. 199986-75-9
CVT-313(NG-26) is a potent, selective, reversible, and ATP-competitive inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 45 | In Stock |
|
| 5MG | 72 | In Stock |
|
| 10MG | 109 | In Stock |
|
| 25MG | 197 | In Stock |
|
| 50MG | 360 | In Stock |
|
| 100MG | 536 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCVT-313
-
NoteResearch use only, not for human use.
-
Brief DescriptionCVT-313(NG-26) is a potent, selective, reversible, and ATP-competitive inhibitor.
-
DescriptionCVT-313 is a potent and selective inhibitor of CDK2 that prevents neointimal proliferation. CVT-313 has an IC50 of 0.5 microM in vitro. Inhibition was competitive with respect to ATP (Ki = 95 nM), and selective CVT-313 had no effect on other, nonrelated ATP-dependent serine/threonine kinases. The growth of mouse, rat, and human cells in culture was also inhibited by CVT-313 with the IC50 for growth arrest ranging from 1.25 to 20 microM. CVT-313 is a promising candidate for evaluation in other disease models related to aberrant cell proliferation.
-
In Vitro——
-
In Vivo——
-
SynonymsCVT-313 | CVT 313 | CVT313
-
PathwayGPCR/G Protein
-
TargetEndothelin Receptor
-
RecptorCDK1| CDK2| CDK4
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number199986-75-9
-
Formula Weight400.47
-
Molecular FormulaC20H28N6O3
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 100 mg/mL; 249.71 mM
-
SMILESCC(C)n1cnc2c1nc(nc2NCc1ccc(cc1)OC)N(CCO)CCO
-
Chemical Name2,2'-((9-isopropyl-6-((4-methoxybenzyl)amino)-9H-purin-2-yl)azanediyl)bis(ethan-1-ol)
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Brooks EE, et al. J Biol Chem. 1997 Nov 14;272(46):29207-11.
molnova catalog
related products
-
BQ-788
BQ-788 is a selective and potent ETB receptor antagonist with potential hypertensive activity.BQ-788 inhibits ET-1 binding to ETB receptors and inhibits exogenous ET-1-induced elevation of coronary artery perfusion pressure.
-
Bosentan
Bosentan is an endothelin (ET) receptor antagonist for ET-A and ET-B with Ki of 4.7 nM and 95 nM, respectively.
-
Bosentan Hydrate
Bosentan is a competitive and dual antagonist of endothelin-1 at the endothelin-A (ET-A) and endothelin-B (ET-B) receptors.
Cart
sales@molnova.com